Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Share-based Compensation (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Share-based Compensation data on record, last reported at $8.0 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 7.27% year-over-year to $8.0 million; the TTM value through Sep 2025 reached $29.6 million, up 12.01%, while the annual FY2024 figure was $27.5 million, 8.88% up from the prior year.
  • Share-based Compensation reached $8.0 million in Q3 2025 per STOK's latest filing, up from $7.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.0 million in Q3 2025 and bottomed at $5.0 million in Q1 2022.
  • Average Share-based Compensation over 4 years is $6.5 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: dropped 8.1% in 2024, then increased 24.82% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $5.8 million in 2022, then rose by 4.63% to $6.1 million in 2023, then grew by 18.34% to $7.2 million in 2024, then increased by 12.14% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $8.0 million in Q3 2025, $7.6 million in Q2 2025, and $6.8 million in Q1 2025.